(Q38849759)

English

Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial

scientific article published on 27 May 2016

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

multicenter clinical trial

0 references

head and neck squamous cell carcinoma

1 reference

based on heuristic

inferred from title

metastatic squamous cell carcinoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Tanguy Y Seiwert

1

object named as

Tanguy Y Seiwert

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

author name string

Barbara Burtness

2

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Ranee Mehra

3

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Jared Weiss

4

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Raanan Berger

5

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Joseph Paul Eder

6

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Karl Heath

7

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Terrill McClanahan

8

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Jared Lunceford

9

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Christine Gause

10

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Jonathan D Cheng

11

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Laura Q Chow

12

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

27 May 2016

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

17

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

956-965

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

The chemoradiation paradigm in head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930066-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Platinum-based chemotherapy plus cetuximab in head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930066-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930066-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Comprehensive genomic characterization of head and neck squamous cell carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930066-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930066-3

7 January 2021

based on heuristic

inferred from DOI database lookup

PD-1 and its ligands in tolerance and immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930066-3

7 January 2021

based on heuristic

inferred from DOI database lookup

PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930066-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930066-3

7 January 2021

based on heuristic

inferred from DOI database lookup

PD-L2 is a second ligand for PD-1 and inhibits T cell activation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930066-3

7 January 2021

based on heuristic

inferred from DOI database lookup

The blockade of immune checkpoints in cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930066-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930066-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930066-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930066-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Pembrolizumab for the treatment of non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930066-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930066-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930066-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Index for rating diagnostic tests

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930066-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Base

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930066-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic significance of human papillomavirus in recurrent or metastatic head and neck cancer: an analysis of Eastern Cooperative Oncology Group trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930066-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Ties that bind: p16 as a prognostic biomarker and the need for high-accuracy human papillomavirus testing.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930066-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Pseudoprogression and Immune-Related Response in Solid Tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930066-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Trial watch: IDO inhibitors in cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930066-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Gene expression profiling in acute allograft rejection: challenging the immunologic constant of rejection hypothesis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930066-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Direct multiplexed measurement of gene expression with color-coded probe pairs

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930066-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(16)30066-3

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38849759&oldid=1790240982"